| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6495534 | PFIZER | Stabilized aqueous suspensions for parenteral use |
May, 2020
(3 years ago) | |
Depo-Subq Provera 104 is owned by Pfizer.
Depo-Subq Provera 104 contains Medroxyprogesterone Acetate.
Depo-Subq Provera 104 has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Depo-Subq Provera 104 are:
- US6495534
Depo-Subq Provera 104 was authorised for market use on 17 December, 2004.
Depo-Subq Provera 104 is available in injectable;subcutaneous dosage forms.
The generics of Depo-Subq Provera 104 are possible to be released after 15 May, 2020.
Drugs and Companies using MEDROXYPROGESTERONE ACETATE ingredient
Market Authorisation Date: 17 December, 2004
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
More Information on Dosage
DEPO-SUBQ PROVERA 104 family patents
